Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/147217
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Montal, Robert | - |
dc.contributor.author | Andreu Oller, Carmen | - |
dc.contributor.author | Bassaganyas, Laia | - |
dc.contributor.author | Esteban Fabró, Roger | - |
dc.contributor.author | Moran, Sebastian | - |
dc.contributor.author | Montironi, Carla | - |
dc.contributor.author | Moeini, Agrin | - |
dc.contributor.author | Pinyol, Roser | - |
dc.contributor.author | Peix, Judit | - |
dc.contributor.author | Cabellos, Laia | - |
dc.contributor.author | Villanueva, Augusto | - |
dc.contributor.author | Sia, Daniela | - |
dc.contributor.author | Mazzaferro, Vincenzo | - |
dc.contributor.author | Esteller, Manel | - |
dc.contributor.author | Llovet i Bayer, Josep Maria | - |
dc.date.accessioned | 2020-01-08T08:39:32Z | - |
dc.date.available | 2020-01-08T08:39:32Z | - |
dc.date.issued | 2019-07-09 | - |
dc.identifier.uri | http://hdl.handle.net/2445/147217 | - |
dc.description.abstract | The clinical utility of serum alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma (HCC) is widely recognised. However, a clear understanding of the mechanisms of AFP overexpression and the molecular traits of patients with AFP-high tumours are not known. We assessed transcriptome data, whole-exome sequencing data and DNA methylome profiling of 520 HCC patients from two independent cohorts to identify distinct molecular traits of patients with AFP-high tumours (serum concentration?>?400?ng/ml), which represents an accepted prognostic cut-off and a predictor of response to ramucirumab. Those AFP-high tumours (18% of resected cases) were characterised by significantly lower AFP promoter methylation (p?<?0.001), significant enrichment of progenitor-cell features (CK19, EPCAM), higher incidence of BAP1 oncogene mutations (8.5% vs 1.6%) and lower mutational rates of CTNNB1 (14% vs 30%). Specifically, AFP-high tumours displayed significant activation of VEGF signalling (p?<?0.001), which might provide the rationale for the reported benefit of ramucirumab in this subgroup of patients. | - |
dc.format.extent | 3 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Nature Publishing Group | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1038/s41416-019-0513-7 | - |
dc.relation.ispartof | British Journal of Cancer, 2019, vol. 121, p. 340–343 | - |
dc.relation.uri | https://doi.org/10.1038/s41416-019-0513-7 | - |
dc.rights | (c) Montal et al., 2019 | - |
dc.source | Articles publicats en revistes (Ciències Fisiològiques) | - |
dc.subject.classification | Càncer de fetge | - |
dc.subject.classification | Oncogènesi | - |
dc.subject.other | Liver cancer | - |
dc.subject.other | Carcinogenesis | - |
dc.title | Molecular portrait of high alpha-fetoprotein in hepatocellular carcinoma: implications for biomarker-driven clinical trials | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 695388 | - |
dc.date.updated | 2020-01-08T08:33:03Z | - |
dc.relation.projectID | info:eu-repo/grantAgreement/EC/H2020/667273/EU//HEP-CAR | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.idimarina | 5706249 | - |
dc.identifier.pmid | 31285588 | - |
Appears in Collections: | Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) Articles publicats en revistes (Ciències Fisiològiques) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
12474_5706249_bjc-afp.pdf | 316.1 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.